Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia

Srdan Verstovsek, Scott Lunin, Hagop Kantarjian, Taghi Manshouri, Stefan Faderl, Jorge Cortes, Francis Giles, Maher Albitar

Research output: Contribution to journalArticle

Abstract

Vascularity is increased in the bone marrow of patients with chronic myeloid leukemia (CML) and high vascular endothelial growth factor (VEGF) levels correlate with worse survival. We analyzed the significance of VEGF-receptor 1 (VEGF-R1) and VEGF-R2 levels in bone marrow samples from 170 CML patients (137 chronic, 24 accelerated, and 9 blastic phase). Median VEGF-R1 and VEGF-R2 levels were 4.66 and 2-fold, respectively, that in normal control samples. Receptor levels did not correlate with disease phase or other host and disease features examined. Chronic phase CML patients with increased VEGF-R2 levels had significantly inferior survival than patients without receptor up-regulation (P=0.009). Patients in accelerated/blastic phase CML with elevated VEGF-R2 expression had marginally worse survival (P=0.05). In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML.

Original languageEnglish (US)
Pages (from-to)661-669
Number of pages9
JournalLeukemia Research
Volume27
Issue number7
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Vascular Endothelial Growth Factor A
Leukemia, Myeloid, Chronic Phase
Survival
Leukemia, Myeloid, Accelerated Phase
Bone Marrow
Up-Regulation

Keywords

  • Angiogenesis
  • Chronic myelogenous leukemia
  • Prognosis
  • VEGF receptors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Verstovsek, S., Lunin, S., Kantarjian, H., Manshouri, T., Faderl, S., Cortes, J., ... Albitar, M. (2003). Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leukemia Research, 27(7), 661-669. https://doi.org/10.1016/S0145-2126(02)00275-8

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. / Verstovsek, Srdan; Lunin, Scott; Kantarjian, Hagop; Manshouri, Taghi; Faderl, Stefan; Cortes, Jorge; Giles, Francis; Albitar, Maher.

In: Leukemia Research, Vol. 27, No. 7, 01.07.2003, p. 661-669.

Research output: Contribution to journalArticle

Verstovsek, S, Lunin, S, Kantarjian, H, Manshouri, T, Faderl, S, Cortes, J, Giles, F & Albitar, M 2003, 'Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia', Leukemia Research, vol. 27, no. 7, pp. 661-669. https://doi.org/10.1016/S0145-2126(02)00275-8
Verstovsek, Srdan ; Lunin, Scott ; Kantarjian, Hagop ; Manshouri, Taghi ; Faderl, Stefan ; Cortes, Jorge ; Giles, Francis ; Albitar, Maher. / Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. In: Leukemia Research. 2003 ; Vol. 27, No. 7. pp. 661-669.
@article{3b7446651f64444fbe8768552fbd22ec,
title = "Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia",
abstract = "Vascularity is increased in the bone marrow of patients with chronic myeloid leukemia (CML) and high vascular endothelial growth factor (VEGF) levels correlate with worse survival. We analyzed the significance of VEGF-receptor 1 (VEGF-R1) and VEGF-R2 levels in bone marrow samples from 170 CML patients (137 chronic, 24 accelerated, and 9 blastic phase). Median VEGF-R1 and VEGF-R2 levels were 4.66 and 2-fold, respectively, that in normal control samples. Receptor levels did not correlate with disease phase or other host and disease features examined. Chronic phase CML patients with increased VEGF-R2 levels had significantly inferior survival than patients without receptor up-regulation (P=0.009). Patients in accelerated/blastic phase CML with elevated VEGF-R2 expression had marginally worse survival (P=0.05). In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML.",
keywords = "Angiogenesis, Chronic myelogenous leukemia, Prognosis, VEGF receptors",
author = "Srdan Verstovsek and Scott Lunin and Hagop Kantarjian and Taghi Manshouri and Stefan Faderl and Jorge Cortes and Francis Giles and Maher Albitar",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0145-2126(02)00275-8",
language = "English (US)",
volume = "27",
pages = "661--669",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia

AU - Verstovsek, Srdan

AU - Lunin, Scott

AU - Kantarjian, Hagop

AU - Manshouri, Taghi

AU - Faderl, Stefan

AU - Cortes, Jorge

AU - Giles, Francis

AU - Albitar, Maher

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Vascularity is increased in the bone marrow of patients with chronic myeloid leukemia (CML) and high vascular endothelial growth factor (VEGF) levels correlate with worse survival. We analyzed the significance of VEGF-receptor 1 (VEGF-R1) and VEGF-R2 levels in bone marrow samples from 170 CML patients (137 chronic, 24 accelerated, and 9 blastic phase). Median VEGF-R1 and VEGF-R2 levels were 4.66 and 2-fold, respectively, that in normal control samples. Receptor levels did not correlate with disease phase or other host and disease features examined. Chronic phase CML patients with increased VEGF-R2 levels had significantly inferior survival than patients without receptor up-regulation (P=0.009). Patients in accelerated/blastic phase CML with elevated VEGF-R2 expression had marginally worse survival (P=0.05). In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML.

AB - Vascularity is increased in the bone marrow of patients with chronic myeloid leukemia (CML) and high vascular endothelial growth factor (VEGF) levels correlate with worse survival. We analyzed the significance of VEGF-receptor 1 (VEGF-R1) and VEGF-R2 levels in bone marrow samples from 170 CML patients (137 chronic, 24 accelerated, and 9 blastic phase). Median VEGF-R1 and VEGF-R2 levels were 4.66 and 2-fold, respectively, that in normal control samples. Receptor levels did not correlate with disease phase or other host and disease features examined. Chronic phase CML patients with increased VEGF-R2 levels had significantly inferior survival than patients without receptor up-regulation (P=0.009). Patients in accelerated/blastic phase CML with elevated VEGF-R2 expression had marginally worse survival (P=0.05). In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML.

KW - Angiogenesis

KW - Chronic myelogenous leukemia

KW - Prognosis

KW - VEGF receptors

UR - http://www.scopus.com/inward/record.url?scp=0037411266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037411266&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00275-8

DO - 10.1016/S0145-2126(02)00275-8

M3 - Article

C2 - 12681367

AN - SCOPUS:0037411266

VL - 27

SP - 661

EP - 669

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -